Literature DB >> 1249582

[Iatrogenic myoclonic encephalopathies caused by bismuth salts].

P Loiseau, P Henry, P Jallon, M Legroux.   

Abstract

Since the beginning of 1974, we have studied 17 cases of iatrogenic encephalopathy due to the ingestion of bismuth taken for the treatment of chronic digestive disorders. More than 100 similar cases have been reported in France within the same period. The clinical picture is remarkably consistent: there is a relatively long prodromal phase with difficulties in gait and writing, followed by a phase characterised by four signs, namely a severe confusional syndrome, myoclonus, astasia-abasia and sisorders of language. In our cases, after withdrawal of bismuth, recovery invariably began within 2 to 3 weeks but fatal cases have been described. All our patients had taken, for periods of between 3 weeks and 20 years, bismuth subnitrate. The levels of bismuth in the blood and urine in these patients were between 10 and 100 times as great as those in patients who had taken the same treatment without ill effect. The exact mechanism by which bismuth causes this complication, described only recently, is totally unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1249582     DOI: 10.1016/0022-510x(76)90056-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Anomalous short plasma elimination half life in a patient intoxicated with bismuth subcitrate.

Authors:  A J McLean; S Islam; J R Lambert
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 2.  Relapse rate as a major determinant of drug selection in peptic ulcer therapy.

Authors:  A J McLean; D M Harcourt; J J McNeil
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

3.  Controlled trial comparing De-Nol tablets with De-Nol liquid in treatment of duodenal ulcer.

Authors:  I Hamilton; A T Axon
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

4.  Antacids for duodenal ulcer.

Authors:  J R Murray
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-04

5.  Adverse effects of anti-ulcer drugs.

Authors:  D A Henry; M J Langman
Journal:  Drugs       Date:  1981-06       Impact factor: 9.546

6.  Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate.

Authors:  P R Froomes; A T Wan; A C Keech; J J McNeil; A J McLean
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer.

Authors:  G Vantrappen; P Rutgeerts; L Broeckaert; J Janssens
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

Review 8.  Pharmacokinetics and toxicity of bismuth compounds.

Authors:  A Slikkerveer; F A de Wolff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.